2024
DOI: 10.3389/fonc.2024.1398902
|View full text |Cite
|
Sign up to set email alerts
|

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

Kevin Miller,
Hamza Hashmi,
Sridevi Rajeeve

Abstract: Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed/refractory multiple myeloma. The current Food and Drug Administration approved CAR T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel both target B cell maturation antigen (BCMA), which is expressed on the surface of malignant plasma cells. Despite deep initial responses in most patients, relapse after anti-BCMA CAR T cell therapy is common. Investigations of acquired resistance to anti-BCMA CA… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 159 publications
0
0
0
Order By: Relevance